Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of neoadjuvant oxaliplatin and 5-fluorouracil in operable oesophageal cancer
2005-001834-34Phase 2Completed
- Sponsor
- Oxford University Hospitals
- Start
- Jan 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and fluorouracil in esophageal cancer, sponsored by Oxford University Hospitals. Primary endpoint: Overall survival. Started Jan 2006; status: completed.
02
Drugs
oxaliplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on 2005-001834-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001834-34.